A negative D-dimer test result alone or combined with low risk clinical status effectively ruled out symptomatic DVT

**QUESTION:** Can a D-dimer assay, alone or combined with clinical examination results, rule out all, proximal, and calf deep venous thrombosis (DVT) in symptomatic patients?

**Description of tests and diagnostic standard**

Patients were classified as being at low, moderate, or high risk for DVT based on a clinical assessment score that included data on the presence of cancer, immobilisation, localised tenderness or leg swelling, family history, history of leg trauma, unilateral pitting oedema or erythema, dilated superficial veins, hospitalisation within 6 months, and erythema of symptomatic leg only. D-dimer levels were assessed by using a rapid whole blood assay (SimpliRED, Agen Biomedical, Brisbane, Australia) by an examiner who was blinded to the clinical findings. DUS (diagnostic standard) was done in a blinded manner to identify all, proximal, and calf DVT. Patients with inconclusive scan results had repeated scans done until the diagnosis was conclusive.

<table>
<thead>
<tr>
<th>Patients</th>
<th>DVT</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>+LR</th>
<th>-LR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Proximal</td>
<td>100%</td>
<td>76%</td>
<td>4.2</td>
<td>0.0</td>
</tr>
<tr>
<td>All</td>
<td>Isolated calf</td>
<td>82%</td>
<td>69%</td>
<td>2.7</td>
<td>0.3</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
<td>91%</td>
<td>82%</td>
<td>5.1</td>
<td>0.1</td>
</tr>
<tr>
<td>High risk</td>
<td>All</td>
<td>100%</td>
<td>47%</td>
<td>1.9</td>
<td>0.0</td>
</tr>
<tr>
<td>Moderate risk</td>
<td>All</td>
<td>75%</td>
<td>78%</td>
<td>3.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Low risk</td>
<td>All</td>
<td>75%</td>
<td>90%</td>
<td>7.5</td>
<td>0.3</td>
</tr>
</tbody>
</table>

**Main results**

Sensitivity and specificity for the diagnosis of DVT for patients with varying risk based on clinical assessment.

**Conclusion**

A negative D-dimer test result, alone or combined with low risk status, effectively ruled out (high sensitivity) all and proximal DVT in symptomatic people.

**COMMENTARY—continued from previous page**

not be as accurate in settings outside the institutions involved in these and similar studies. Thus, the study results that pertain to calf DVT should be interpreted with caution.

When the study results were limited to proximal DVT, the combination of a negative D-dimer test result and a low clinical likelihood effectively excluded proximal DVT in about 99% of patients. Another noteworthy finding is that the D-dimer test is not sufficiently accurate to be used as a "stand alone" test in patients with suspected DVT. Although Lennox and colleagues reported a sensitivity of 100% with D-dimer alone for proximal DVT, this finding is based on relatively few patients. In the study by Aschwanden and colleagues, the sensitivity of D-dimer for proximal DVT, 89%, was lower than that reported in other studies and may reflect a higher proportion of patients with less extensive DVT and the inclusion of patients with previous DVT. Patients with previous DVT may have a persistently abnormal DUS in the absence of acute DVT.

Clinicians should be aware that D-dimer tests may show false negative results in patients with small popliteal DVT or calf DVT and in patients with biochemically inactive DVT who undergo testing > 14 days after the onset of symptoms and in patients with cancer. Furthermore, the accuracy of D-dimer testing varies depending on the assay used. Thus, a structured history and clinical examination is an integral component in the evaluation of patients with suspected DVT.

Are the results of these studies sufficient to change current clinical practice? Not yet. Before DUS can be rendered unnecessary in patients with suspected DVT who have a low clinical likelihood and a negative D-dimer test result, prospective studies with important clinical outcomes are needed to validate the safety of this management approach. Additional research questions include the clinical utility of D-dimer testing in patients with suspected recurrent DVT and in patients who are receiving anticoagulant therapy.

James Douketis, MD
St Joseph’s Hospital
Hamilton, Ontario, Canada